Chronic Myeloid Leukemia Preceded by Tuberculosis-Reference-Cited by-同舟云学术

Chronic Myeloid Leukemia Preceded by Tuberculosis

Published:2020-06-24 Issue:2 Volume:13 Page:708-711
ISSN:1662-6575
Container-title:Case Reports in Oncology
language:en
Short-container-title:Case Rep Oncol

Author:

Al-Qudah Bara M.,Yassin Mohamed A.,Abdulla Mohammad A.J.,Aldapt Mahmood S.,Abufaied Mohamad M.

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, classically described as a triphasic disease. However, little is known about risk factors for developing CML. Currently, ionizing radiation is the only established risk factor. Here, we report on a 37-year-old man treated for tuberculosis; 2 years later, he developed CML in a chronic phase. We would like to shed light on tuberculosis as a possible risk factor for CML.

Publisher

S. Karger AG

Subject

Oncology

Reference8 articles.

1. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010 Nov;116(19):3724–34.

2. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul;341(3):164–72.

3. Al-Dewik NI, Morsi HM, Samara MM, Ghasoub RS, Gnanam CC, Bhaskaran SK, et al. Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clin Med Insights Oncol. 2016 Jan;10:95–104.

4. Vezzalini M, Mafficini A, Tomasello L, Lorenzetto E, Moratti E, Fiorini Z, et al. A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients. J Hematol Oncol. 2017 Dec;10(1):129.

5. Tomasello L, Vezzalini M, Boni C, Bonifacio M, Scaffidi L, Yassin M, et al. Regulative loop between β-catenin and protein tyrosine receptor type γ in chronic myeloid leukemia. Int J Mol Sci. 2020;21(7):2298